New oral chronic lymphocytic leukaemia treatment made available on NHS
AstraZeneca’s Calquence (acalabrutinib), a chemotherapy-free monotherapy, will be offered to patients with chronic lymphocytic leukaemia.
List view / Grid view
News
Novel blood cleansing device to enter first-in-human trial
The Garnet™ therapeutic product, which can capture more than 100 clinically relevant bacteria, fungi, parasites, toxins and viruses from the blood, will soon begin clinical testing.
EMA clears use of COVID-19 Vaccine AstraZeneca
The EMA’s drug safety committee concluded that the vaccine is not associated with an increased risk of thromboembolic events and that its benefits still outweigh its risks.
International trade officials to review impact of pharma mergers
The Federal Trade Commission will work with international regulators to review the effects of pharma mergers and update approaches to analysing them.
Aspirin may decrease ICU admission and death in COVID-19 patients
In a new study, low dose aspirin reduced risk of mechanical ventilation, ICU admission and in-hospital mortality by over 40 percent each.
Gilead and Merck to collaborate on long-acting HIV treatments
The companies have agreed to jointly develop and commercialise long-acting, investigational treatment combinations of lenacapavir and islatravir for HIV.
Drug-eluting contact lens shows potential in first-in-human study
The LLT-BMT1 drug releasing contact lens was safe, well tolerated and may have reduced the incidence of hyperaemia in an early glaucoma trial.
Moderna begins testing its COVID-19 vaccine in paediatric patients
The Phase II/III trial will assess the safety and efficacy of the COVID-19 Vaccine Moderna in children aged six months to less than 12 years.
VS-01 shows promise in Phase Ib decompensated liver cirrhosis trial
The first-in-human trial showed VS-01 is safe and generated improvements in selected biomarkers and clinical cognitive tests in patients with decompensated liver cirrhosis.
Data shows long-term efficacy of Tremfya® in active psoriatic arthritis
The joint and skin response rates of adults with active psoriatic arthritis observed with Tremfya® (guselkumab) were maintained over two years.
bluebird bio releases new data on its gene therapy for cerebral adrenoleukodystrophy
Data from nearly seven years of follow up suggests one-time treatment with eli-cel may durably stabilise cerebral adrenoleukodystrophy disease progression.
CRISPR therapies could be one of the most transformative in human history, says GlobalData
Adam Pearson, Senior Oncology Analyst at GlobalData, comments on the development of CRISPR-based therapies and outlines potential opportunities and challenges in the space.
Salbutamol significantly increases cerebral perfusion in proof-of-concept trial
In the Phase I trial, the beta-2 adrenoceptor agonist salbutamol significantly increased cerebral perfusion, a key biomarker in neurodegenerative disease.
Fujifilm to launch rapid antigen COVID-19 test in Europe
Having received the CE certificate, Fujifilm can now launch its highly-sensitive, rapid antigen test kit for SARS-CoV-2 in Europe.
Libtayo® improves overall survival in advanced cervical cancer patients
A Phase III trial evaluating Libtayo® (cemiplimab) monotherapy in advanced cervical cancer has been stopped early due to a positive result on overall survival.
